GI Dynamics to Release 2016 Annual Report and Host Webcast for Year Ending 31 December 2016
March 22 2017 - 5:00PM
Business Wire
GI Dynamics, Inc. (ASX: GID), a medical device company that has
commercialized EndoBarrier® in Europe and the Middle East for
patients with type 2 diabetes and obesity, announced that it will
release its 2016 Annual Report on Form 10K on or before 31 March
EDT | 1 April AEDT 2017.
The company will host a conference call and webcast at 5 PM EDT
29 March 2017 | 8 AM AEDT 30 March 2017.
Webcast
The webcast and presentation, which will provide a financial
update on GI Dynamics, can be accessed at
https://event.webcasts.com/starthere.jsp?ei=1141206 or on the GI
Dynamics website, www.gidynamics.com, by clicking on the Investor
Relations tab and going to the Events and Webcasts page.
A copy of the presentation and a transcript for the call will be
available on the company’s website.
About GI Dynamics
GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier,
the first endoscopically delivered device approved for the
treatment of type 2 diabetes and obesity. EndoBarrier is approved
and commercially available in multiple countries outside the United
States. EndoBarrier is not approved for sale in the United
States and is limited by federal law to investigational use only in
the United States. Founded in 2003, GI Dynamics is headquartered in
Boston, Massachusetts. For more information, please
visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains forward-looking statements concerning
our development and commercialization plans, potential revenues and
revenue growth, costs, excess inventory, profitability and
financial performance, ability to obtain reimbursement for our
products, clinical trials and associated regulatory submissions and
approvals, the number and location of commercial centers offering
the EndoBarrier, and our intellectual property position. These
forward-looking statements are based on GI Dynamics’ management’s
current estimates and expectations of future events as of the date
of this announcement. Furthermore, the estimates are subject to
several risks and uncertainties that could cause actual results to
differ materially and adversely from those indicated in or implied
by such forward-looking statements. These risks and uncertainties
include but are not limited to, risks associated with the
consequences of terminating the ENDO trial and the possibility that
future clinical trials will not be successful or confirm earlier
results. Further risks are associated with obtaining funding from
third parties; the timing and costs of clinical trials; the timing
of regulatory submissions; and the timing, receipt and maintenance
of regulatory approvals. The timing and amount of other expenses
and the timing and extent of third-party reimbursement risks
associated with commercial product sales, including product
performance, competition, risks related to market acceptance of
products, intellectual-property risk; risks related to excess
inventory; and risks related to assumptions regarding the size
of the available market, the benefits of our products, product
pricing, timing of product launches, future financial results and
other factors, including those described in our filings with the
U.S. Securities and Exchange Commission. Given these uncertainties,
one should not place undue reliance on these forward-looking
statements. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information or future events or otherwise, unless we are required
to do so by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170322006343/en/
Investor RelationsUnited States:GI Dynamics, Inc.Monica
Bellevue, +1 781-357-3246Investor Relations
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Apr 2023 to Apr 2024